Computationally restoring the potency of a clinical antibody against Omicron.

doi:10.1038/s41586-024-07385-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Computationally restoring the potency of a clinical antibody against Omicron.

Nature - 1 May 2024

Desautels Thomas A, Arrildt Kathryn T, Zemla Adam T, Lau Edmond Y, Zhu Fangqiang, Ricci Dante, Cronin Stephanie, Zost Seth J, Binshtein Elad, Scheaffer Suzanne M, Dadonaite Bernadeta, Petersen Brenden K, Engdahl Taylor B, Chen Elaine, Handal Laura S, Hall Lynn, Goforth John W, Vashchenko Denis, Nguyen Sam, Weilhammer Dina R, Lo Jacky Kai-Yin, Rubinfeld Bonnee, Saada Edwin A, Weisenberger Tracy, Lee Tek-Hyung, Whitener Bradley, Case James B, Ladd Alexander, Silva Mary S, Haluska Rebecca M, Grzesiak Emilia A, Earnhart Christopher G, Hopkins Svetlana, Bates Thomas W, Thackray Larissa B, Segelke Brent W, Lillo Antonietta Maria, Sundaram Shivshankar, Bloom Jesse D, Diamond Michael S, Crowe James E, Carnahan Robert H, Faissol Daniel M

Abstract excerpt

The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs1-3 and revealed how quickly viral escape can curtail effective options4,5. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab4-6. Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Antibodies, Neutralizing

Share to Antibodies, Viral

Share to COVID-19

Share to Drug Design

Share to Neutralization Tests

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 38720086
DOI: 10.1038/s41586-024-07385-1
PMCID: PMC11111397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computationally restoring the potency of a clinical antibody against Omicron.PMID 38720086Read ↗

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariantsSemantic proximity Read ↗

Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineeringSemantic proximity Read ↗

Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron VariantsSemantic proximity Read ↗

Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1.Semantic proximity Read ↗

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.Semantic proximity Read ↗

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSemantic proximity Read ↗

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escapeSemantic proximity Read ↗

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.Semantic proximity Read ↗

Deep learning-guided selection of antibody therapies with enhanced resistance to current and prospective SARS-CoV-2 Omicron variantsSemantic proximity Read ↗

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responsesSemantic proximity Read ↗

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1Semantic proximity Read ↗

Investigating the structural impact of Omicron RBD mutation on antibody escape and receptor management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.